Curcumin suppresses the accretion of breast cancer partially by mediating the immune system. Recent research has indicated that curcumin could prevent the loss of T cells and inhibit immune suppressive cytokines, including transforming grow factor beta (TGF-) and interleukin 10 (IL-10) in carcinogenesis. Particularly, tumor exosome-mediated inhibition of nature killer cell magnification was partially reversed by curcumin through the impairment of a ubiquitinproteasome system. Moreover, curcumin acted as an inhibitor of the MEK/ERK signaling passageway, correspondingly preventing tumor-dependent TGF–induced Tregulatory cell proliferation. Curcumin after that suppresses the adding happening of breast cancer by affecting metastasis factors in two ways (Fig. 3). First, curcumin inhibited angiogenesis factors, such as vascular endothelial gathering factor (VEGF) and basic fibroblast enhancement factor (bFGF), in ER-negative breast cancer cells. Meanwhile, Carroll et al. reported that curcumin could suppress the secretion of angiogenesis factors, as one complication of medroxyprogesterone acetate. Second, curcumin in addition to affects metastasis factors through belligerence. Curcumin not unaccompanied limited the exposure to setting of adhesion molecules (such as integrin 64) and the cytoskeleton protein (such as matrix metalloproteinase 9 and intercellular adhesion molecule 1), but furthermore blocked recepteur dorigine nantais (RON) tyrosine kinase-mediated forcefulness. Moreover, it is qualified that curcumin prevents hematogenous metastases in immunodeficient models.